High-affinity T cell receptors for adoptive cell transfer
Ariel Isser1 and Jonathan P. Schneck2,3
1Department of Biomedical Engineering,
2Department of Pathology, Medicine and Oncology, and
3Immunology Program, Institute of Cellular Engineering, Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA.
Address correspondence to: Jonathan Schneck, Department of Pathology, Johns Hopkins University School of Medicine, 733 N. Broadway, Miller Research Building Room 639, Baltimore, Maryland 21205, USA. Phone: 410.614.4589; Email: jschnec1@jhmi.edu.
Find articles by Isser, A. in: JCI | PubMed | Google Scholar
1Department of Biomedical Engineering,
2Department of Pathology, Medicine and Oncology, and
3Immunology Program, Institute of Cellular Engineering, Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA.
Address correspondence to: Jonathan Schneck, Department of Pathology, Johns Hopkins University School of Medicine, 733 N. Broadway, Miller Research Building Room 639, Baltimore, Maryland 21205, USA. Phone: 410.614.4589; Email: jschnec1@jhmi.edu.
Find articles by Schneck, J. in: JCI | PubMed | Google Scholar
First published December 10, 2018 - More info
J Clin Invest. 2019;129(1):69–71. https://doi.org/10.1172/JCI125471.
Copyright © 2019, American Society for Clinical Investigation
Adoptive cell transfer (ACT) of engineered T cell receptors (TCRs) for cancer immunotherapy has evolved from simple gene transfer of isolated TCRs to various affinity enhancement techniques that overcome limitations imposed by central and peripheral tolerance on TCR affinity. In the current issue of the JCI, Poncette et al. used mice with human TCRαβ and HLA gene loci to discover CD4+ TCRs of optimal affinity for cancer testis antigen (CTA) NY-ESO-1. They combined this TCR with a previously discovered NY-ESO-1–specific CD8+ TCR in an ACT fibrosarcoma tumor model to demonstrate the importance of T cell help in mediating antitumor responses.
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Individual online subscriptions ordered from September 1st on will receive access for the remainder of current year as well as for the full following year subscription term.
- Print subscription
- $830
- Individual print subscriptions give you the print journal and full online access for the year.
- JCI This Month subscription
- $125
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $225.
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)